The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF. The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes. Diabetes 2002, 51: 797-802. PMID: 11872682, PMCID: PMC2995527, DOI: 10.2337/diabetes.51.3.797.Peer-Reviewed Original ResearchMeSH KeywordsAdipocytesAdipose TissueBlood GlucoseBody CompositionCalorimetry, IndirectDiabetes Mellitus, Type 2Fatty AcidsGlucose Clamp TechniqueGlycated HemoglobinGlycerolHumansHyperinsulinismInsulinKineticsLipidsLipolysisLiverMagnetic Resonance SpectroscopyMicrodialysisMiddle AgedMuscle, SkeletalOxidation-ReductionRosiglitazoneThiazolesThiazolidinedionesTriglyceridesConceptsPlasma fatty acid concentrationsMuscle triglyceride contentEffects of rosiglitazoneType 2 diabetesInsulin sensitivityPeripheral adipocytesTriglyceride contentRosiglitazone treatmentFatty acid concentrationsTwo-step hyperinsulinemic-euglycemic clampSkeletal muscle triglyceride contentType 2 diabetic subjectsInsulin-stimulated glucose metabolismWhole-body insulin sensitivityExtramyocellular lipid contentInsulin-responsive organHepatic triglyceride contentHyperinsulinemic-euglycemic clampAdipocyte insulin sensitivityDiabetic subjectsInsulin clampGlucose metabolismGlycerol releaseResponsive organSubcutaneous fat